Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Altamira Therapeutics Ltd. - Common Shares
(NQ:
CYTO
)
0.3001
UNCHANGED
Streaming Delayed Price
Updated: 3:55 PM EST, Dec 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Altamira Therapeutics Ltd. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
December 20, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 06, 2024
Via
Benzinga
Altamira Therapeutics Provides Update on Nasdaq Listing
October 04, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
September 27, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
September 24, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
September 20, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
September 19, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
September 17, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
September 16, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
September 03, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
August 23, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
August 16, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
August 15, 2024
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news today!
Via
InvestorPlace
Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
August 15, 2024
Via
Benzinga
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
August 12, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
July 19, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
June 20, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Provides Business Update
May 28, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Hunting For Gains In Penny Stocks
May 26, 2024
On Thursday, I saw that some penny stocks were already trading over 100 million shares, with others around 30 million. It was clear: penny stocks were in focus. Here’s how the trades went down.
Via
Talk Markets
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
May 24, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
12 Health Care Stocks Moving In Thursday's Intraday Session
May 23, 2024
Via
Benzinga
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
May 24, 2024
From
FN Media Group LLC
Via
GlobeNewswire
What's Going On With Altamira Therapeutics Stock?
May 23, 2024
Altamira Therapeutics shares are trading higher Thursday after the company announced highlights from its NASAR clinical trial with Bentrio nasal spray were published in video format on the social media...
Via
Benzinga
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
May 23, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
May 01, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
April 24, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 22, 2024
Via
Benzinga
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
April 10, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Earnings Scheduled For April 10, 2024
April 10, 2024
Companies Reporting Before The Bell • Delta Air Lines (NYSE:DAL) is projected to report quarterly earnings at $0.35 per share on revenue of $12.55 billion.
Via
Benzinga
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
April 04, 2024
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.